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To the Editor, 
The management of patients with colo-rectal liver metastases has improved significantly 
over the recent years. However, most patients still cannot undergo complete resection, 
generally because the location of the metastases within the liver prevents any radical 
management, and explaining the interest for transplantation. The first attempts were 
performed in the eighties with poor outcomes, in part due to a high proportion of death 
not related to the neoplastic disease (1). More recently, the group of Oslo has shown a 
60% five-year survival, in 21 patients with colo-rectal metastases (2). Such a survival 
was better than the one expected on chemotherapy alone (2-4). However, 95% (20/21) of 
patients had cancer recurrence, most within the first 18 months after transplantation. At 
present, liver transplantation for colo-rectal metastases remains highly controversial. The 
potential for long-term disease-free survival needs to be explored, which is the aim of this 
multi-centric collaborative retrospective study.  
A total of 12 patients (6 females/6 males) underwent liver transplantation for colo-rectal 
liver metastasis, at centers affiliated to the “Compagnons Hépato-Bilaires”, an association 
of hepato-pancreato-biliary and transplant surgeons, most trained at the Paul Brousse 
Hospital, Paris, France under the guidance of Professor H. Bismuth. Median age at 
transplant was 56 years (Table 1). Patients were managed in Lisbon (n=8), Coimbra 
(n=2), Paris (n=1), and Geneva (n=1) between October 1995 and October 2015 (date of 
transplant), and no other patient underwent transplantation for this indication at these 
respective transplant centers. Data collection was conducted according the relevant 
ethical standards at each institution. The location of the primary adenocarcinoma was the 
colon in 11 patients, and the rectum in one. Most primary cancers were T3 on pathology, 
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and many presented between 1 and 3 involved –N1– lymph nodes (two patients were N2 
with more than 3 nodes involved, Table 1).  
For most patients, liver metastases (9/12) were diagnosed within 12 months after the 
diagnosis of the primary cancer, and were considered as synchronous. When not 
diagnosed at the same time as the primary, liver metastases were discovered 4, 7, 19, 24 
and 29 months after the primary. At the time of transplantation, patients presented a 
median of 9 liver metastases. Two had lesions >5 cm, of 5.5 and 8 cm. Median CEA level 
was 16.9 µg/l, and one patients had CEA >200 µg/l, of 314 µg/l. 
Most (11/12) patients received chemotherapy prior to transplantation. Chemotherapy 
included irinotecan and oxaliplatin in 9 (82%) patients, and a biological agent in 6 
(cetuximab in 2, bevacizumab in 3, and both agents in 1). Another patient was treated by 
intra-hepatic chemotherapy prior to transplantation. All patients responded to 
chemotherapy, and none was in progression at the time of the transplantation. The 
decision to conduct a post-transplant adjuvant chemotherapy was based, at least in the 
recent years, on the aim to obtain a minimum of four months of peri-transplant 
oxaliplatine and/or irinotecan-including chemotherapy. It was used in four patients. 
Overall, most patients underwent complex, long-term chemotherapy treatment, with a 
median of two lines (1 in 1 patient, 2 in 6 patients, 3 in 2 patients, and 4 in 1 patient). 
In addition to chemotherapy, 10 patients underwent liver metastasis resection, in one 
(n=5), two (n=3), or three (n=2) procedures, one of which was a two-stage resection. One 
patient underwent radio-frequency ablation (RFA) as part of the treatment. At the time of 
transplantation, any treatment by resection or RFA was not possible anymore. 
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Transplantations were performed 41 (12-97) months after the resection of the primary. 
Liver grafts were from 6 non-marginal donors after brain-death, 5 domino donors with 
familial amyloid polyneuropathy, and one living-related donor. Transplantation was part 
of a planned treatment strategy following previous liver resection in 6 patients. In 2 
patients, transplantation was performed upfront without previous resection, considered 
impossible because of diffuse liver disease. In three patients, transplantations were 
performed as salvage procedures: after massive bleeding (and packing) following liver 
resection, for a failed associating liver partition and portal vein ligation for staged 
hepatectomy (ALPPS) procedure, and for post-resection liver failure. Finally, one patient 
was transplanted with inferior vena cava replacement due to tumor invasion. Overall, 6 
patients could be categorized as having planned transplantations, and 6 patients could be 
retrospectively considered as having received “compassioned” transplantations.  
The median length of hospital stay for transplantation was 16 days. Seven patients had 
complications, including 3 patients with grade 2 complications according to Clavien-
Dindo (pneumonia and fever of unknown origin treated by antibiotics, and rejection 
treated by steroids), 1 patients with grade 3b complication (biliary leak requiring 
endoscopic stenting), 2 patients with grade 4a complication (kidney failure requiring 
dialysis, prolonged ventilation requiring a tracheostomy), and 1 patient with grade 5 
complication (death following severe bleeding and shock). Eight patients received mTOR 
inhibitors as part of their maintenance immunosuppression.  
Overall patient survivals were 83 ±11 %, 62 ±15 %, and 50 ±16 % at 1, 3 and 5 years, 
after a median follow-up of 26 (0-108) months (Figure 1). Six patients had a recurrence, 
affecting the lungs (n=5), the liver (n=3), and the peritoneum (n=1). Disease-free 
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survivals were 56 ±14 %, 38 ±15 %, and 38 ±15 % at 1, 3 and 5 years. Treatment of 
recurrence included palliative chemotherapy in five patients and radiotherapy in one. Five 
patients were alive and free of cancer 7, 43, 47, 48, and 108 months after transplantation 
(Table 1).  
Patients undergoing transplantation for compassionate indications (upfront, salvage, and 
vena cava involvement) had significantly worse disease-free survivals than patients with 
planned indications (p=0.02). Looking at the Oslo criteria (2), the last pre-transplant CEA 
level (≥80 vs. <80 µg/l, p=0.09) and the time between resection of the primary cancer and 
transplantation (≥24 vs. <24 months, p=0.01) also tended to predict disease-free survival. 
The size of the largest metastasis at transplant (≥5.5 vs. <5.5 cm) failed to predict 
survival (p=0.47).  
As a whole, the present investigation goes one step further compared to the Norwegian 
experience, as it demonstrates that disease-free survival can be achieved. However, such 
an outcome was only seen in patients after transplantation performed as deliberate 
procedures in a long-term treatment (n=6). These patients had previously undergone a 
combined oncological/surgical management with multiple courses of chemotherapy, and 
often multiple liver resections. None had a progressive disease at the time of 
transplantation. Conversely, the six patients with upfront, emergency, and extrahepatic 
disease transplantations (“compassionate” indications) did significantly worse, and most 
had a recurrence within 18 months, suggesting that transplantation in these situations 
must be avoided. 
In addition, the present cohort shows that the time between colo-rectal surgery and 
transplantation (with a cut-off at 24 months) and the last CEA level (80 µg/l) tend to 
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predict disease-free survival, while tumor diameter (<5.5 cm) and cancer progression (no 
patient in progression) could not be identified. These factors as a whole should be used 
and refined for selecting patients for prospective trials (short time between primary and 
transplant, low CEA, small lesion, without progression)(2).  
Of note, the Norwegian experience (21 published patients) has been possible thanks to 
the unique high organ donor availability in this country, where the recipient needs are 
covered within a short waiting time. In all other countries, the lack of donors represent a 
major challenge to transplantation for colo-rectal liver metastasis. Outcomes still need to 
be improved and validated before potentially justifying a systematic use of liver grafts for 
this indication on a common waiting list with patients with end-stage liver failure and 
hepatocellular carcinoma. In the meantime, domino, and living-donor liver grafts should 
be favored, and the RAPID concept further explored (5). In addition, current 
transplantation for non-resectable colo-rectal metastasis should be conducted within 
prospective trials with strict inclusion and exclusion criteria.  
The present study should be seen as a proof-of-feasibility, demonstrating the potential of 
achieving disease-free survival after transplantation colo-rectal metastases in a 
meaningful proportion of patients. It should encourage turning away from more 
emotional indications, in favor of prospective studies with strict selection criteria to 
explore the potential of this modality. 
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“Compagnons Hépato-bilio-pancréatiques” group 
The “compagnons hépato-pancréato-biliaires” include hepato-pancreato-biliary and 
transplant surgeons, most trained in the Paul Brousse hospital. The following experts 
have been contacted in view of a workshop in Porto Alegre (April 2016), and have 
contributed to the work:   
Rene Adam (Hôpital Paul Brousse, Villejuif, France), Dimitri Alden (New York, USA), 
Malcolm Aldridge (East and North Hertfordshire NHS, Hertford, UK), Oscar Andriani 
(Hospital Universitario Austral, Buenos Aires, Argentina), Arie Ariche (West Galile 
Medical Center, Nahariyya, Israel), Ibrahim Astarcioglu (Genel Cerrahi Anabilim Dali, 
Izmir, Turkey), Eduardo Barroso (Hospital de Curry Cabral, Lisbon, Portugal), 
Abdelkader Belkouchi, Hopital Avicenne, Rabbat, Maroc), Henri Bismuth (Hôpital Paul 
Brousse, Villejuif, France), Fernando Buabse (San Miguel de Tucuman, Argentina), 
Fulvio Calise (Ospedale Cardarelli, Napoli, Italy), Enrique Miguel Canepa (Hospital 
Privado de Comunidad, Cordoba, Argentina), Francisco Castro Sousa (Coimbra 
University Hospital, Coimbra, Portugal), Daniel Cherqui (Hopital Paul-Brousse, 
Villejuif, France), Laurence Chiche (Bordeaux University Hospital, Bordeaux, France), 
Miguel Ciardullo (Hospital Italiano, Buenos Aires, Argentina), Pierre-Alain Clavien 
(Zurich University Hospital, Zurich, Switzerland), Marvin Corlette (Belmont, CA, USA), 
Guido Costamagna (Universita Cattolica de Sacre Cuore, Rome, Italy), Joao Coutinho 
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(Hospital St Maria, Lisbon, Portugal), Ignazia Demma (Anthea Hospital, Bari, Italy), 
Tom Diamond (Queen’s University, Belfast, UK), Jiahong Dong (Chinese PLA General 
Hospital Chinese Beijing, China), Jean Edmond (Columbia University, New York, USA), 
Rachad El-Masry (Ahmed Maher Teaching Hospital , Cairo , Egypt), Rony Eshkenazy 
(Sheba Medical Center, Tel-Aviv, Israel), Olivier Farges (Hopital Beaujon, Clichy, 
France), Cyrille Feray (Hôpital Henri-Mondor, Paris, France), Dominique Franco 
(Hopital Antoine-Béclère, Clamart, France), Francisco Navarro Freire (University of 
Granada, Granada, Spain), O James Garden (University of Edinburgh, Edinburgh, UK), 
Jean-François Gigot (Cliniques Universitaires Saint Luc, Bruxelles, Belgium), Jean 
Gugenheim (Hopital de l’Archet II, Nice, France), Nagy Habib (Hammersmith Hospital, 
London, UK), Ellen Hagopian (Jersey Shore University Medical Center, New Jersey, 
USA), Emir Hoti (St Vincent’s University Hospital, Dublin, Ireland), John Isaac (Queen 
Elizabeth Medical Centre, Birmingham, UK), Marc Johann (Hopitaux Privés de Metz, 
Metz, France), Ousmane Ka (Université Cheikh Anta Diop, Dakar, Senegal), Antonio 
Kalil (Hospital Moinhos de Vento, Porto Alegre, Brazil),  Andreas Katz (Greenville 
Medical Tower, Texas, USA), Jina Krissat (Blackpool Victoria Hospital, Blackpool, 
UK), Réal Lapointe (Centre Hospitalier de l’Université de Montréal, Montréal, Canada), 
Jan Lerut (Cliniques Universitaires Saint Luc, Bruxelles, Belgium), Cristiano Xavier 
Lima (Hospital Felice Rocho, Belo Horizonte, Brazil), Marcelo Linhares (Universidade 
Federal de Sao Paulo, Sao Paulo, Brazil), Valerio Lucidi (Erasme University Hospital, 
Bruxells Belgium), Pietro Majno (Geneva University Hospital, Geneva, Switzerland), 
Stelios Mantonakis (Errikos Dynan Hospital, Athens, Greece), Surendra Kumar Mathur 
(Medical College & BYL Nair Hospital, Mumbai, India),  Francesco Meriggi (University 
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of Pavia, Pavia, Italy), Mario Morino (Istituto di Clinica e Terapia Chirurgica, Torino, 
Italy), Richard Nakache (Tel-Aviv Souraski Medical Center, Tel-Aviv, Israel), Benoit 
Navez (Cliniques Universitaires Saint-Luc, Bruxelles, Belgium), Gennaro Nuzzo 
(Hepatobiliary Unit Largo R, Roma, Italy), Roger Obregon (Federal University of Sao 
Paulo, Sao Paulo, Brazil), Raul Oleas (Quito, Ecuador), Jorge Paulino (Hospital de Curry 
Cabral, Lisbon, Portugal), Riccardo Pellicci (Ospedale Santa Corona, Pietra Ligure, 
Italy), Hugo Pinto Marques (Hospital de Curry Cabral, Lisbon, Portugal), Joseph Raccuia 
(New York University Langone Medical Center, New York, USA), Juan Manuel Rico 
Juri (Imbanaco Medical Center, Cali, Colombia), Antonio Robecchi (Turin, Italy), 
Rodolfo Rossi (Sanatoria Mater Dei, Buenos Aires, Argentina), Daradkeh Salam (Jordan 
University, Amman, Jordan), Faouzi Saliba (Hôpital Paul Brousse, Villejuif, France), 
Didier Samuel (Hopital Paul Brousse, Villejuif, France), Carlos Eduardo Santos 
(National Cancer Institute of Brazil, Botafogo, Brazil), Sabine Sarnacki-Feray (Hopital 
Necker, Paris, France), Tzyy-Yuan Shann (Auckland, New Zealand), David Sherlock 
(North Manchester General Hospital, Manchester, UK), Daniel Shouval (Hadassah 
Hebrew University Hospital, Jerusalem, Israel), Christian Toso (Geneva University 
Hospital, Geneva, Switzerland), Oscar Traynor (National Surgical Training Centre, 
Dublin, Ireland), Françoise Van Hove (Hôpital Paul Brousse, Villejuif, France), Corinne 
Vons (Hopital Jean-Verdier, Paris, France), Raja Wakim (Mount Lebanon Hospital, 
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Table 1: characteristics of patients 
 
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Patient 9 Patient 10 Patient 11 Patient 12
Status
Alive without 
cancer
Alive without 
cancer
Alive without 
cancer
Alive without 
cancer
Alive without 
cancer
Dead with 
cancer
Dead with 
cancer
Dead with 
cancer
Dead with 
cancer
Alive with 
cancer
Dead with 
cancer
Dead 
without 
cancer
Time since transplantation (months)* 7 43 47 48 108 7 20 8 14 32 41 0
Time from transplant to recurrence (months) NA NA NA NA NA 3 7 8 10 12 31 NA
Age at transplant (years) 65 56 73 54 54 58 38 38 56 56 61 59
Gender F M M M F F F F M F M M
Location of primary cancer Colon Rectum Colon Colon Colon Colon Colon Colon Colon Colon Colon Colon
TNM of primary T4N1M1 T4N1M1 T3N1M1 T3N0M0 T2N0M0 T0N0M1 T3N0M1 T3N2M0 T3N2M1 T3N0M1 T3N1M1 T3N1M0 
Time from primary to metastases (months) 0 0 0 7 29 0 0 24 0 0 29 4
Time from primary to transplant (months) 92 39 80 73 97 43 14 32 12 86 29 16
Largest metastasis at transplantation (cm) 3 2 2 1 8 40 55 15 40 15 20 60
Number of metastases at transplant 2 9 10 1 2 >15 >15 1 multiple >15 1 3
CEA at transplantation (µg/l) 2 59 8 1 26 174 5 4 NA 314 NA NA
Chemotherapy base prior to transplant O/I O/I O/I O/I O/I O/I O/I O/I noO noI O/I no chemo noO noI
Chemotherapy biological agent prior to transplant beva none cetux cetux beva beva + cetux none none none beva no chemo none
Number of resections prior to transplant 1 3 1 2 3 2 0 1 0 2 1 1
Grey background shows patients with ongoing disease-free survival, White background shows patients with recurrence and/or death
* until last follow-up (for the patients 1 to 5, and 10) or death 
CEA: carcinoembryonic antigen, O/I: oxaliplatin/irinotecan, NA: not available or not applicable
Beva: bevacizumab, Cetux: cetuximab
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Figure legends 
Figure 1: Overall (full line) and disease-free (dashed line) survivals 
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